Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.
Molecular Partners AG's Net-Net Working Capital for the quarter that ended in Mar. 2026 was CHF1.63.
The industry rank for Molecular Partners AG's Net-Net Working Capital or its related term are showing as below:
XSWX:MOLN's Price-to-Net-Net-Working-Capital is ranked better than 80.79% of 859
companies
in the Biotechnology industry
Industry Median: 5.4
vs XSWX:MOLN: 1.94
Molecular Partners AG (XSWX:MOLN) Net-Net Working Capital Explanation
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.
Molecular Partners AG Net-Net Working Capital Related Terms
Molecular Partners AG Net-Net Working Capital Historical Data
* Premium members only.
The historical data trend for Molecular Partners AG's Net-Net Working Capital can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Molecular Partners AG Net-Net Working Capital Chart
XSWX:MOLN vs VRTX, REGN, ALNY: Net-Net Working Capital Comparison
For the Biotechnology subindustry, Molecular Partners AG's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Molecular Partners AG Price-to-Net-Net-Working-Capital vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Molecular Partners AG's Price-to-Net-Net-Working-Capital distribution charts can be found below:
* The bar in red indicates where Molecular Partners AG's Price-to-Net-Net-Working-Capital falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.
In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
This is a conservative way of estimating the company's value.
What does a Net-Net Working Capital of CHF1.63 mean?
Molecular Partners AG (XSWX:MOLN) has a Net-Net Working Capital of CHF1.63 as of Mar. 2026. Ben Graham defined net-net working capital as the per-share sum of cash, 75% of receivables and 50% of inventory less total liabilities. View historical data on Molecular Partners AG According to the industry distribution chart, Molecular Partners AG ranks #165 out of 859 companies in the Biotechnology industry, placing it in the top 19.2%.
Is Molecular Partners AG's Net-Net Working Capital too high?
Molecular Partners AG's current Net-Net Working Capital is CHF1.63. Based on the distribution chart, Molecular Partners AG ranks #165 out of 859 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Molecular Partners AG has a GF Score™ of 29/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Molecular Partners AG's Net-Net Working Capital compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Molecular Partners AG ranks #165 out of 859 companies for Net-Net Working Capital. This places Molecular Partners AG in the top 19% of its industry — outperforming the majority of peers. The industry median Net-Net Working Capital is 5.40. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net-Net Working Capital for a Biotechnology company?
The median Net-Net Working Capital among Biotechnology companies is 5.40, based on 859 companies in the industry. Companies in the top quartile (top 25%) have a Net-Net Working Capital significantly above this median, while those in the bottom quartile fall well below. However, Net-Net Working Capital should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net-Net Working Capital mean?
A high Net-Net Working Capital can signal that a stock is expensive relative to its fundamentals. Ben Graham defined net-net working capital as the per-share sum of cash, 75% of receivables and 50% of inventory less total liabilities. View historical data on Molecular Partners AG For the Biotechnology industry, the median Net-Net Working Capital is 5.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Molecular Partners AG's current Net-Net Working Capital is CHF1.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Molecular Partners AG stock overvalued right now?
Based on GuruFocus' analysis, Molecular Partners AG (XSWX:MOLN) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF0.37, compared to a current price of CHF3.16 — trading 754.1% above its estimated fair value. The current Net-Net Working Capital is CHF1.63. Molecular Partners AG's overall GF Score™ is 29/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net-Net Working Capital calculated?
Net-Net Working Capital is calculated from a company's financial statements. For Molecular Partners AG (XSWX:MOLN), the current Net-Net Working Capital is CHF1.63 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Molecular Partners AG (XSWX:MOLN) Overvalued in 2026?
Based on GuruFocus' analysis, Molecular Partners AG stock appears to be overvalued.
The current stock price of CHF3.16 is trading 754.1% above its estimated GF Value™ of CHF0.37.
GuruFocus considers Molecular Partners AG to be Significantly Overvalued.
Key valuation signals for XSWX:MOLN:
Net-Net Working Capital: CHF1.63
GF Value™: CHF0.37 vs. price of CHF3.16 (754.1% above fair value)
No single metric tells the full story. See the XSWX:MOLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.
29GF Score
Get the complete analysis for XSWX:MOLN
Net-Net Working Capital is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:MOLN has been successfully added to your 
